This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 95/6/587    most recent 01.RES.0000142317.88591.e6v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, J. Articles by Pagano, P. J. Search for Related Content PubMed PubMed Citation Articles by Liu, J. Articles by Pagano, P. J. Related Collections Remodeling Hypertrophy Other Vascular biology

(Circulation Research. 2004;95:587.)
© 2004 American Heart Association, Inc.

Molecular Medicine

Gene Transfer of NAD(P)H Oxidase Inhibitor to the Vascular Adventitia Attenuates Medial Smooth Muscle Hypertrophy

Jianhua Liu, Adrian Ormsby, Nancy Oja-Tebbe, Patrick J. Pagano

From the Hypertension and Vascular Research Division (J.L., P.J.P.), Pathology-Lab Medicine Division (A.O.) and Biostatistics Department (N.O-T.), Henry Ford Hospital, Detroit, Mich.

Correspondence to Patrick J. Pagano, PhD, E & R Building, Rm 7044, Hypertension and Vascular Research Division, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI 48202-2689. E-mail ppagano1{at}hfhs.org

We previously showed that a systemic inhibitor of gp91^phox (nox2)-based NAD(P)H oxidase abolishes angiotensin II (Ang II)–induced vascular hypertrophy. In the present study, we tested whether perivascular transfection with Ad-gp91ds-eGFP (an adenoviral bicistronic construct targeting NAD(P)H oxidase in fibroblasts) or controls Ad-CMV-eGFP and Ad-scrmb-eGFP would affect medial hypertrophy in response to Ang II. In C57BL/6J mice, we applied Ad-gp91ds-eGFP or controls to the left carotid adventitia, and 2 days later we implanted minipumps delivering vehicle or Ang II (750 µg/kg per day) for 7 days. None of the viral treatments affected Ang II–induced systolic blood pressure elevation. Immunohistochemical staining showed marker eGFP in adventitial fibroblasts and some macrophages, indicating expression of the gp91ds inhibitor. As expected, Ang II induced medial hypertrophy (medial cross-sectional area, 32.96±2.04 versus 20.57±1.00x10³ µm², Ang II versus control; P<0.001) that was significantly inhibited by Ad-gp91ds-eGFP (26.23±0.90x10³ µm²; P<0.01) but not control viruses. Application of viruses alone did not change medial size under control conditions. Immunohistochemical staining and semiquantitative analysis showed a 70% increase in reactive oxygen species levels measured by the lipid peroxidation byproduct 4-hydroxynonenal (4-HNE) throughout the carotid wall in the Ang II group versus vehicle. After treatment with Ad-gp91ds-eGFP, 4-HNE generation was normalized. Thus NAD(P)H oxidases in adventitial fibroblasts and macrophages appear to modulate Ang II–induced medial hypertrophy.

Key Words: NAD(P)H oxidase • reactive oxygen species • hypertrophy • gene therapy • angiotensin II

This article has been cited by other articles:

				D. A. Towler Oxidation, Inflammation, and Aortic Valve Calcification: Peroxide Paves an Osteogenic Path J. Am. Coll. Cardiol., September 2, 2008; 52(10): 851 - 854. [Full Text] [PDF]

				C.-X. Lin, N.-E. Rhaleb, X.-P. Yang, T.-D. Liao, M. A. D'Ambrosio, and O. A. Carretero Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1253 - H1261. [Abstract] [Full Text] [PDF]

				R. C.M. Siow and A. T. Churchman Adventitial growth factor signalling and vascular remodelling: Potential of perivascular gene transfer from the outside-in Cardiovasc Res, September 1, 2007; 75(4): 659 - 668. [Abstract] [Full Text] [PDF]

				M. J. Haurani and P. J. Pagano Adventitial fibroblast reactive oxygen species as autacrine and paracrine mediators of remodeling: Bellwether for vascular disease? Cardiovasc Res, September 1, 2007; 75(4): 679 - 689. [Abstract] [Full Text] [PDF]

				S. J. An, R. Boyd, M. Zhu, A. Chapman, D. R. Pimentel, and H. D. Wang NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts Cardiovasc Res, September 1, 2007; 75(4): 702 - 709. [Abstract] [Full Text] [PDF]

				E. C. Chan, S. R. Datla, R. Dilley, H. Hickey, G. R. Drummond, and G. J. Dusting Adventitial application of the NADPH oxidase inhibitor apocynin in vivo reduces neointima formation and endothelial dysfunction in rabbits Cardiovasc Res, September 1, 2007; 75(4): 710 - 718. [Abstract] [Full Text] [PDF]

				T. Szasz, K. Thakali, G. D. Fink, and S. W. Watts A Comparison of Arteries and Veins in Oxidative Stress: Producers, Destroyers, Function, and Disease Experimental Biology and Medicine, January 1, 2007; 232(1): 27 - 37. [Abstract] [Full Text] [PDF]

				S. D. Hingtgen, X. Tian, J. Yang, S. M. Dunlay, A. S. Peek, Y. Wu, R. V. Sharma, J. F. Engelhardt, and R. L. Davisson Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy Physiol Genomics, September 14, 2006; 26(3): 180 - 191. [Abstract] [Full Text] [PDF]

				C. E. Murdoch, M. Zhang, A. C. Cave, and A. M. Shah NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure Cardiovasc Res, July 15, 2006; 71(2): 208 - 215. [Abstract] [Full Text] [PDF]

				P. J. Pagano and M. J. Haurani Vascular Cell Locomotion: Osteopontin, NADPH Oxidase, and Matrix Metalloproteinase-9 Circ. Res., June 23, 2006; 98(12): 1453 - 1455. [Full Text] [PDF]

				C.-F. Lai, V. Seshadri, K. Huang, J.-S. Shao, J. Cai, R. Vattikuti, A. Schumacher, A. P. Loewy, D. T. Denhardt, S. R. Rittling, et al. An Osteopontin-NADPH Oxidase Signaling Cascade Promotes Pro-Matrix Metalloproteinase 9 Activation in Aortic Mesenchymal Cells Circ. Res., June 23, 2006; 98(12): 1479 - 1489. [Abstract] [Full Text] [PDF]

				M. Weaver, J. Liu, D. Pimentel, D. J. Reddy, P. Harding, E. L. Peterson, and P. J. Pagano Adventitial delivery of dominant-negative p67phox attenuates neointimal hyperplasia of the rat carotid artery Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1933 - H1941. [Abstract] [Full Text] [PDF]

				K. R. Stenmark, N. Davie, M. Frid, E. Gerasimovskaya, and M. Das Role of the Adventitia in Pulmonary Vascular Remodeling Physiology, April 1, 2006; 21(2): 134 - 145. [Abstract] [Full Text] [PDF]

				P. L. Hordijk Regulation of NADPH Oxidases: The Role of Rac Proteins Circ. Res., March 3, 2006; 98(4): 453 - 462. [Abstract] [Full Text] [PDF]

				N. Ardanaz and P. J. Pagano Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Experimental Biology and Medicine, March 1, 2006; 231(3): 237 - 251. [Abstract] [Full Text] [PDF]

				T. Kawahara, D. Ritsick, G. Cheng, and J. D. Lambeth Point Mutations in the Proline-rich Region of p22phox Are Dominant Inhibitors of Nox1- and Nox2-dependent Reactive Oxygen Generation J. Biol. Chem., September 9, 2005; 280(36): 31859 - 31869. [Abstract] [Full Text] [PDF]

				F. A. Yaghini, C. Zhang, J.-H. Parmentier, A. M. Estes, N. Jafari, S. A. Schaefer, and K. U. Malik Contribution of Arachidonic Acid Metabolites Derived Via Cytochrome P4504A to Angiotensin II-Induced Neointimal Growth Hypertension, June 1, 2005; 45(6): 1182 - 1187. [Abstract] [Full Text] [PDF]